Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BECONASE vs UNI-DUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
FDA-approved: Management of seasonal or perennial allergic rhinitis,Off-label: Nonallergic rhinitis, nasal polyps, adjunctive treatment for sinusitis
Treatment of asthma (chronic stable and acute exacerbations),Chronic obstructive pulmonary disease (COPD) maintenance therapy,Apnea of prematurity (off-label),Ureteral colic (off-label)
1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.
200-400 mg orally every 12 hours; maximum 800 mg daily.
1.5-3 hours (terminal elimination half-life); no accumulation with once-daily dosing.
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
Primarily hydrolyzed by esterases in the lung, liver, and plasma to its active metabolite beclomethasone-17-monopropionate (17-BMP). Further metabolism via CYP3A4 to inactive metabolites.
Theophylline is primarily metabolized in the liver by cytochrome P450 enzymes CYP1A2 (major) and CYP2E1, CYP3A4 (minor). It undergoes N-demethylation and oxidation to form metabolites (1-methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid). Approximately 10% is excreted unchanged in urine.
Primarily hepatic metabolism; <10% excreted renally as unchanged drug; biliary/fecal excretion accounts for minimal elimination.
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
87% bound to plasma proteins, primarily corticosteroid-binding globulin and albumin.
95% bound to albumin.
0.5-1.5 L/kg; indicates extensive distribution into tissues.
Vd 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid.
Intranasal: <1% systemic absorption due to extensive first-pass metabolism and local administration.
Oral: 85-95% (immediate-release); 70-80% (extended-release).
No adjustment required.
GFR 30-50 m L/min: 200 mg every 12 hours; GFR <30 m L/min: 200 mg every 24 hours; hemodialysis: 200 mg after dialysis.
No adjustment required.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: 200 mg every 24 hours.
Children 6-11 years: 1 spray (42 mcg) per nostril twice daily; children ≥12 years: same as adult.
5-10 mg/kg orally every 12 hours; maximum 400 mg daily.
No specific adjustment; use lowest effective dose.
Initiate at 200 mg every 12 hours; increase cautiously, monitor renal function.
None
WARNING: Life-threatening adverse events, including seizures, cardiac arrhythmias, and respiratory arrest, can occur with theophylline toxicity. Serum theophylline levels must be monitored closely, and dosing adjusted to maintain therapeutic range (5-15 mcg/m L). Concurrent use with other xanthines (e.g., caffeine) is contraindicated.
Risk of suppression of hypothalamic-pituitary-adrenal (HPA) axis with prolonged use at higher than recommended doses,Possible development of localized Candida albicans infections of the nose and pharynx,Caution in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex,Use with caution in patients with recent nasal ulcers, nasal surgery, or nasal trauma until healing has occurred
Therapeutic drug monitoring required due to narrow therapeutic index. Caution in patients with hepatic impairment, heart failure, pneumonia, elderly, and fever (prolonged half-life). Drug interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., smoking, rifampin). Seizure risk at high levels. Cardiotoxicity (atrial/ventricular arrhythmias).
Hypersensitivity to beclomethasone dipropionate or any component of the formulation,Untreated localized nasal mucosal infections (e.g., herpes simplex)
Hypersensitivity to theophylline or any component. Concurrent use with ephedrine or other xanthines. Active seizure disorder (relative). Uncontrolled cardiac arrhythmias. Severe hepatic impairment.
No specific food interactions reported. Beconase is administered intranasally and has negligible systemic absorption, so dietary restrictions are not required.
Food does not affect absorption significantly; however, consistent dietary caffeine intake may increase side effects. A high-protein, low-carbohydrate diet can decrease theophylline clearance; avoid drastic dietary changes.
Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major congenital malformations or adverse fetal outcomes. However, the potential for fetal harm cannot be completely ruled out. Trimester-specific risks: First trimester: No evidence of teratogenicity in animal studies at clinically relevant doses, but human data are limited. Second and third trimesters: No increased risk of fetal growth restriction or adrenal suppression reported, but high doses may theoretically affect fetal adrenal function.
Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood flow, growth restriction, and premature labor inhibition. Avoid use unless benefit outweighs risk.
Inhaled beclomethasone is not expected to be present in breast milk in significant amounts due to low systemic bioavailability. The M/P ratio is not available. Manufacturer advises caution, but risk to infant is low. Use while breastfeeding is considered acceptable if maternal benefit outweighs potential risk.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance to mother.
No dose adjustment is generally required for inhaled beclomethasone during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered clearance) are not clinically significant for inhaled corticosteroids due to minimal systemic absorption. However, ensure the lowest effective dose is used to maintain asthma control.
No standard dose adjustments. Increased clearance and volume of distribution during pregnancy may require dose titration based on clinical response and serum drug levels if applicable.
Beconase (beclomethasone dipropionate) is an intranasal corticosteroid for allergic rhinitis. Onset of action is not immediate; regular use for several days to weeks is required for full effect. Priming the nasal spray with 6 sprays before first use is essential. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. For best results, administer after clearing nasal passages. Systemic absorption is minimal at recommended doses, but monitor for growth suppression in children with prolonged high-dose use.
UNI-DUR (theophylline extended-release) requires monitoring of serum theophylline concentrations to maintain efficacy and avoid toxicity; therapeutic range is 5-15 mcg/m L. Avoid use in patients with active peptic ulcer disease or seizure disorders. Dosage adjustments needed in hepatic impairment, heart failure, and with concurrent use of drugs that affect CYP1A2 and CYP3A4.
Use Beconase regularly as prescribed, not for immediate symptom relief.,Prime the spray with 6 test sprays before first use or if not used for 7 days.,Blow nose gently before dosing to clear nasal passages.,Tilt head forward, insert nozzle into nostril, and spray away from the septum.,Avoid spraying into eyes or on the nasal septum.,Do not exceed recommended dosage; side effects are rare but include nasal irritation or nosebleeds.,Inform your doctor if symptoms do not improve after 3 weeks.,If also using a decongestant spray, use the decongestant first, then wait 10-15 minutes before Beconase.
Take UNI-DUR exactly as prescribed, at the same time each day, with or without food.,Do not crush or chew the tablets; swallow whole.,Avoid smoking and limit caffeine intake as they can alter theophylline levels.,Report symptoms of toxicity such as nausea, vomiting, insomnia, palpitations, or seizures.,Do not change brands or formulations without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BECONASE vs UNI-DUR, answered by our medical review team.
BECONASE is a Nasal Corticosteroid that works by Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.. UNI-DUR is a Methylxanthine Bronchodilator that works by UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BECONASE and UNI-DUR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BECONASE is: 1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.. The standard adult dose of UNI-DUR is: 200-400 mg orally every 12 hours; maximum 800 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BECONASE and UNI-DUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BECONASE is classified as Category C. Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major co. UNI-DUR is classified as Category C. Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.